CIAS
CRL icon

CBIZ Investment Advisory Services’s Charles River Laboratories CRL Stock Holding History

CBIZ Investment Advisory Services’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$152 – 699
2025
Q2 		$152 Buy
+1
New +$133 ﹤0.01% 701

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

CBIZ Investment Advisory Services's CRL Position: Q3 2025 in Review

CBIZ Investment Advisory Services sold out of Charles River Laboratories (CRL) in Q3 2025, closing a stake of 1 share — an estimated $152 sold.

CBIZ Investment Advisory Services first reported a position in CRL in Q2 2025 and held it in 1 quarter. The position peaked at $152 in Q2 2025. 556 funds tracked by Wall St. Rank hold CRL as of Q3 2025.

  • CBIZ Investment Advisory Services reported no remaining Charles River Laboratories position as of Q3 2025 after selling out during the quarter.
  • CBIZ Investment Advisory Services sold 1 Charles River Laboratories share in Q3 2025, an estimated $152.
  • CBIZ Investment Advisory Services first reported a position in Charles River Laboratories in Q2 2025 and held it in 1 quarter.
  • CBIZ Investment Advisory Services's Charles River Laboratories position peaked at $152 in Q2 2025.
  • 556 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2025.

Based on CBIZ Investment Advisory Services's 13F filing for Q3 2025, filed 6 Nov 2025.